Elaine R Mardis from the Nationwide Children’s Hospital & Ohio State University College of Medicine, OH, US, and AACR President-Elect (2018–2019), talks to us about her upcoming role and how AACR aims to meet unmet needs in cancer research and personalized medicine in the future.
1. What are the main aims of the American Association for Cancer Research (AACR)? (0:08)
2. What do you anticipate to be the major challenges of your role as president of the AACR? (0:31)
3. What have been the most exciting developments in the genomic characterization of cancer in the past year? (1:35)
4. What are the major unmet needs in personalized cancer medicine? (2:19)
5. What do you expect to be the key themes of the AACR annual meeting? (3:24)Speaker disclosures: Elaine R Mardis has nothing to disclose in relation to this video interview.
Filmed at the American Association for Cancer Research (AACR) Annual Meeting 2018, Chicago, IL, US, April 14–18, 2018.
Share this Video
Related Videos In Haematological Malignancies
Binod Dhakal, ASCO 2023: The CARTITUDE-4 trial, ciltacabtagene autoleucel for patients with lenalidomide-refractory multiple myeloma
Lenalidomide is a standard of care in multiple myeloma. But with the prevalence of the lenalidomide-refractory population increasing, the CARTITUDE-4 trial aimed to assess ciltacabtagene autoleucel for this patient population. In this touchONCOLOGY interview, we speak with Dr Binod Dhakal (Medical College of Wisconsin, Milwaukee, WI, USA) to discuss the mechanism of action of ciltacabtagene […]
Binod Dhakal, ASCO 2023: The treatment paradigm for multiple myeloma
The treatment paradigm for patients with multiple myeloma is very complex. In this touchONCOLOGY interview, we speak with Dr Binod Dhakal (Medical College of Wisconsin, Milwaukee, WI, USA) to break down the treatment paradigm in multiple myeloma, discussing how to handle different patient cases. The abstract entitled ‘First phase 3 results from CARTITUDE-4: Cilta-cel versus […]
ZUMA-23 study of axicabtagene ciloleucel as first-line therapy in large B-cell lymphoma: Jason Westin, EHA 2023
ZUMA-23 (NCT05605899) is an on-going phase 3 study investigating axicabtagene ciloleucel (axi-cel) CAR T cell therapy as a first-line therapy in patients with high-risk large B-cell lymphoma. touchONCOLOGY caught up with Dr Jason Westin (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) to discuss what previous clinical trials have taught us about […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!